CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Choueiri, TK; Halabi, S; Sanford, B; Hahn, O; Michaelson, MD; Walsh, M; Olencki, T; Picus, J; Small, EJ; Dakhil, S; George, D; Morris, MJ

Published Date

  • October 1, 2016

Published In

Volume / Issue

  • 27 /

Start / End Page

  • vi566 -

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

International Standard Serial Number (ISSN)

  • 0923-7534

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdw435.23

Citation Source

  • Scopus